Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants

Journal of Viral Hepatitis

Volumn 12, Issue 4, 2005, Pages 364-372

  Van Der Eijk, A A ^a   Hansen, B E ^a   Niesters, H G M ^a   Janssen, H L A ^a   Van De Ende, M ^a   Schalm, S W ^a   De Man, Robert A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Hepatitis B virus; Hepatitis B virus deoxyribonucleic acid levels; Lamivudine; Tenofovir; Viral dynamics

Indexed keywords

ADEFOVIR DIPIVOXIL; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ADD ON THERAPY; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG EFFICACY; DYNAMICS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MATHEMATICAL MODEL; NEPHROTOXICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTANT; VIRUS REPLICATION;

ADENINE; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHOSPHONIC ACIDS; VIRAL LOAD; VIRUS REPLICATION;

EID: 21844431630     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00620.x     Document Type: Article

References (29)

1. Perrillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323(5): 295-301.
2. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119(4): 312-323.
3. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46(4): 562-568.
4. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119(1): 172-180.
5. Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32(4 Pt 1): 828-834.
6. van der Eijk AA, Niesters HG, Pas SD, de Man RA. Persistence of YMDD variants after withdrawal of lamivudine. J Hepatol 2002; 36(2): 304-305.
7. Stuyver LJ, Locarnini SA, Lok A et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33(3): 751-757.
8. Niesters HG, de Man RA, Pas SD, Fries E, Osterhaus AD. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J Med Microbiol 2002; 51(8): 695-699.
9. Niesters HG, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus AD. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998; 177(5): 1382-1385.
10. Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000; 7(2): 161-165.
11. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348(2): 177-178.
12. Bruno R, Sacchi P, Zocchetti C, Ciappina V, Puoti M, Filice G. Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. AIDS 2003; 17(5): 783-784.
13. Nelson M, Portsmouth S, Stebbing J et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003; 17(1): F7-F10.
14. Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16(17): 2352-2354.
15. Ristig MB, Crippin J, Aberg JA et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002; 186(12): 1844-1847.
16. van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002; 36(2): 507-508.
17. van Bommel F, Schernick A, Hopf U, Berg T. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology 2003; 124(2): 586-587.
18. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282(5386): 103-107.
19. Wolters LM, Hansen BE, Niesters HG, Zeuzem S, Schalm SW, de Man RA. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver 2002; 22(2): 121-126.
20. Pas SD, Fries E, de Man RA, Osterhaus AD, Niesters HG. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 2000; 38(8): 2897-2901.
21. Heermann KH, Gerlich WH, Chudy M, Schaefer S, Thomssen R. Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. Eurohep Pathobiology Group. J Clin Microbiol 1999; 37(1): 68-73.
22. Stuyver L, Van Geyt C, De Gendt S et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000; 38(2): 702-707.
23. Osterhaus AD, Vos MC, Balk AH et al. Transmission of hepatitis B virus among heart transplant recipients during endomyocardial biopsy procedures. J Heart Lung Transplant 1998; 17(2): 158-166.
24. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999; 29(6): 1863-1869.
25. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93(9): 4398-4402.
26. Neumann AU, Ronen T, Tsiang M et al. Predictive HBeAg loss by HBV DNA early kinetics and HBV genotype during treatment of HBeAg+ chronic hepatitis B (CHB) patients with adefovir dipivoxil (ADV). J Hepatol 2003; 38 (Suppl. 2): 26.
27. Benhamou Y, Bochet M, Thibault V et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358(9283): 718-723.
28. Wolters LM, Hansen BE, Niesters HG et al. The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. J Hepatol 2002; 37(2): 253-258.
29. Lewin SR, Ribeiro RM, Walters T et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001; 34(5): 1012-1020.